Biomarker ID | 55 |
PMID | 15609297 |
Year | 2005 |
Biomarker | DDR/PCA3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (140 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(PCA3):-CHEK1 knockdown 136 GSE31534,PIK3CA mutant 27 GDS4053 |
Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 18 patients with prostate cancer and 35 patients with Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
Senstivity | BPH Predicion: 97.1% |
Specificity | PCa Prediction: 77.8% |
AUC | NA |
Accuracy | 90.6% |
Level Of Significance | p=0.007 |
Method Used | RT-PCR |
Clinical | No |
Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | PCA3 |